SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

• Published in: Nephrology, dialysis, transplantation Vol. 38; no. 11; pp. 2444 - 2455
• Main Authors: Mark, Patrick B, Sarafidis, Pantelis, Ekart, Robert, Ferro, Charles J, Balafa, Olga, Fernandez-Fernandez, Beatriz, Herrington, William G, Rossignol, Patrick, Del Vecchio, Lucia, Valdivielso, Jose M, Mallamaci, Francesca, Ortiz, Alberto, Nistor, Ionut, Cozzolino, Mario
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 31.10.2023
• Subjects: Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Diabetes Mellitus, Type 2 - complications; Heart Failure - complications; Humans; Life Sciences; Renal Dialysis - adverse effects; Renal Insufficiency, Chronic; Review; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; diabetic kidney disease; heart failure; cardiovascular; chronic renal failure; cardiorenal syndrome

ABSTRACT Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for...